Cart
sales@molnova.com
Afatinib dimaleate
CAS No. 850140-73-7
Afatinib dimaleate ( BIBW 2992MA2;BIBW-2992;BIBW2992;BIBW 2992;Afatinib )
Catalog No. M16171 CAS No. 850140-73-7
An irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 31 | In Stock |
|
| 10MG | 49 | In Stock |
|
| 25MG | 71 | In Stock |
|
| 100MG | 129 | In Stock |
|
| 200MG | 178 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAfatinib dimaleate
-
NoteResearch use only, not for human use.
-
Brief DescriptionAn irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively.
-
DescriptionAn irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively; shows high selectivity over HGFR, c-Src, β-InsRK,VEGFR2; suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models.Lung Cancer Approved
-
SynonymsBIBW 2992MA2;BIBW-2992;BIBW2992;BIBW 2992;Afatinib
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR(L858R);EGFR(L858R/T790M);EGFR(wt);HER2
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number850140-73-7
-
Formula Weight718.08
-
Molecular FormulaC32H33ClFN5O11
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 35 mg/mL
-
SMILESCN(C/C=C/C(=O)NC1=C(C=C2N=CN=C(C2=C1)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4COCC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O
-
Chemical Name2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:2) (9CI)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li D, et al. Oncogene. 2008 Aug 7;27(34):4702-11.
2. Perera SA, et al. Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):474-9.
3. Takezawa K, et al. Mol Cancer Ther. 2010 Jun;9(6):1647-56.
2. Perera SA, et al. Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):474-9.
3. Takezawa K, et al. Mol Cancer Ther. 2010 Jun;9(6):1647-56.
molnova catalog
related products
-
BPR1J-097
BPR1J-097 is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).
-
PD 089828
PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM)
-
AST-1306
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R.
